Hikma Pharmaceuticals upgrades 2013 revenue outlook

Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".

Shares in Hikma Pharmaceuticals rose Thursday after the company upgraded its 2013 revenue growth forecast following a "strong start to the year".

The group expects revenue to rise 13% this year, up from its previous guidance of 10%, driven by the performance of Branded and Injectables and Generics businesses in the year-to-date.

The Branded and Injectables unit is on track to meet the firm's full-year guidance while the Generics arm is continuing to benefit from its doxycycline product which is delivering revenue ahead of forecasts.

"We have made a very good start to 2013 across all of our businesses and I am pleased to be able to raise our group guidance for the full year," said Chief Executive Officer Said Darwazah.

The company's branded business was boosted by the introduction of new products and enhancements in sales and marketing activities. The unit has experienced improvement in markets including Algeria, Egypt and Saudi Arabia.

In January, Hikma completed the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries which has since been fully integrated.

Branded revenue is expected to increase 11% in 2013, with a slight improvement in adjusted operating margin.

The Injectables division has been performing well in the US, supported by new product launches, price improvements and our continued focus on operational efficiencies.

Full-year guidance for the Generics business is for revenue of $150m and operating margin in the low teens.

"Overall, our diversified business model is positioning the group to deliver another strong year in 2013," Arabia said.

Shares climbed 2.32% to 1,014p at 12:43 Thursday.

RD

Recommended

Imperial Brands has an 8.3% dividend yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% dividend yield – but what’s the catch?

With an impressive dividend yield of 8.3%, Imperial Brands looks to be one of the most attractive income stocks in the FTSE 100 . But investors should…
6 Jul 2022
Can Royal Mail continue to deliver its 7.6% yield?
Share tips

Can Royal Mail continue to deliver its 7.6% yield?

Royal Mail shares are yielding 7.6% this year. But it’s facing some huge challenges, says Rupert Hargreaves. So is Royal Mail’s dividend sustainable?
6 Jul 2022
Saga’s figures are heading in the right direction – so should you buy?
Share tips

Saga’s figures are heading in the right direction – so should you buy?

Saga the over-50s travel and financial services specialist, has been struggling for years. But now, with the pandemic behind, it it is planning for fu…
5 Jul 2022
Director dealings w/e 1 July: what company insiders are buying and selling
Stocks and shares

Director dealings w/e 1 July: what company insiders are buying and selling

Directors’ share dealings can often give investors an insight into the sentiment of company insiders. Here are some of the biggest deals by company di…
5 Jul 2022

Most Popular

Ray Dalio’s shrewd $10bn bet on the collapse of European stocks
European stockmarkets

Ray Dalio’s shrewd $10bn bet on the collapse of European stocks

Ray Dalio’s Bridgewater hedge fund is putting its money on a collapse in European stocks. It’s likely to pay off, says Matthew Lynn.
3 Jul 2022
Persimmon yields 12.3%, but can you trust the company to deliver?
Share tips

Persimmon yields 12.3%, but can you trust the company to deliver?

With a dividend yield of 12.3%, Persimmon looks like a highly attractive prospect for income investors. But that sort of yield can also indicate compa…
1 Jul 2022
Is inflation about to drop as recession takes hold?
UK Economy

Is inflation about to drop as recession takes hold?

Central banks are raising interest rates in an attempt to curb soaring inflation. But will that push the economy into recession? John Stepek looks at …
5 Jul 2022